<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Monte Rosa Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc</link>
<description>Latest news and press releases for Monte Rosa Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/monte-rosa-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835785378dffbe2df0f800d.webp</url>
<title>Monte Rosa Therapeutics Inc</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc</link>
</image>
<item>
<title>Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-presents-preclinical-data-at-american-association-for-cancer-research-aacr-annual-meeting-2026-on-the-potential-of-its-cyclin-e1-ccne1-directed-molecular-glue-degrader-to-treat-ccne1-amplified-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-presents-preclinical-data-at-american-association-for-cancer-research-aacr-annual-meeting-2026-on-the-potential-of-its-cyclin-e1-ccne1-directed-molecular-glue-degrader-to-treat-ccne1-amplified-solid-tumors</guid>
<pubDate>Mon, 20 Apr 2026 11:00:00 GMT</pubDate>
<description>CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectivity and reduced off-target activity compared to CDK2 inhibitors Oral presentation on April 21, 2026, at 2:30 p.m. PT BOSTON, April 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based med</description>
</item>
<item>
<title>Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-business-updates</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP</description>
</item>
<item>
<title>Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-clinical-supply-agreement-to-support-phase-2-trial-evaluating-mrt-2359-in-combination-with-apalutamide-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-clinical-supply-agreement-to-support-phase-2-trial-evaluating-mrt-2359-in-combination-with-apalutamide-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with</description>
</item>
<item>
<title>Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-presents-updated-clinical-data-from-phase-12-study-of-mrt-2359-in-combination-with-enzalutamide-in-heavily-pretreated-metastatic-castration-resistant-prostate-cancer-patients-at-asco-genitourinary-cancers-symposium-asco-gu</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-presents-updated-clinical-data-from-phase-12-study-of-mrt-2359-in-combination-with-enzalutamide-in-heavily-pretreated-metastatic-castration-resistant-prostate-cancer-patients-at-asco-genitourinary-cancers-symposium-asco-gu</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5</description>
</item>
<item>
<title>Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-pricing-034900567</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-pricing-034900567</guid>
<pubDate>Fri, 09 Jan 2026 03:49:00 GMT</pubDate>
<description>BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price</description>
</item>
<item>
<title>Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-proposed-210100743</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-proposed-210100743</guid>
<pubDate>Wed, 07 Jan 2026 21:01:00 GMT</pubDate>
<description>BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All of the shares of common stock and pre-funded warrants to purchase</description>
</item>
<item>
<title>Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-positive-120000136</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-positive-120000136</guid>
<pubDate>Wed, 07 Jan 2026 12:00:00 GMT</pubDate>
<description>In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and durable reductions in systemic inflammation After four weeks of MRT-8102 treatment, C-reactive protein (CRP) levels were reduced by 85%, and 94% of study participants achieved CRP values below 2 mg/L, a threshold associated with reduced cardiovascular disease (CVD) risk Single ascend</description>
</item>
<item>
<title>Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-present-interim-210500810</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-present-interim-210500810</guid>
<pubDate>Tue, 06 Jan 2026 21:05:00 GMT</pubDate>
<description>Conference call and webcast to be held at 8 a.m. ET on January 7, 2026BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Wednesday, January 7, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1 study of the NEK7-directed MGD</description>
</item>
<item>
<title>Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-compelling-120000575</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-compelling-120000575</guid>
<pubDate>Tue, 16 Dec 2025 12:00:00 GMT</pubDate>
<description>In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, including 2 patients with RECIST responses and 2 with stable disease Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events Company plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 targeting AR mutant and AR signaling-dependent</description>
</item>
<item>
<title>Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-present-updated-210100726</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-present-updated-210100726</guid>
<pubDate>Mon, 15 Dec 2025 21:01:00 GMT</pubDate>
<description>Conference call and webcast to be held at 8 a.m. ET on December 16, 2025BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Tuesday, December 16, 2025, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1/2 study of the GSPT1-d</description>
</item>
<item>
<title>Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-presents-preclinical-163000777</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-presents-preclinical-163000777</guid>
<pubDate>Sat, 08 Nov 2025 16:30:00 GMT</pubDate>
<description>Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis Initial data from a Phase 1 study of MRT-8102 in healthy volunteers and elevated CVD-risk subjects on track for first half of 2026 Poster presentation on November 8 at 10:30 a.m. CST BOSTON, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stag</description>
</item>
<item>
<title>Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-third-120000300</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-third-120000300</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise payments, milestones, and tiered royalties Phase 1 study of NEK7-directed MGD MRT-8102 underway, investigating a potential novel approach to treat inflammatory diseases driven by the NLRP3 inflammasome; initial readout including data from high-CVD risk cohort on track for H1 2026 VAV1-directe</description>
</item>
<item>
<title>Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-participate-upcoming-120000516</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-participate-upcoming-120000516</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference (Boston, MA) – November 10, 2025, at 11:30 a.m. ETTD Cowen Immunology & Inflammation Summit (virtual) – November</description>
</item>
<item>
<title>Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-presents-preclinical-110000346</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-presents-preclinical-110000346</guid>
<pubDate>Fri, 24 Oct 2025 11:00:00 GMT</pubDate>
<description>MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model Data support the potential of MRT-6160 to address multiple rheumatic autoimmune and inflammatory diseases, including Sjögren’s disease, systemic lupus erythematosus, and rheumatoid arthritis Poster presentation on October 26th at 10:30 am CDT BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics</description>
</item>
<item>
<title>Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-collaboration-110000189</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-collaboration-110000189</guid>
<pubDate>Mon, 15 Sep 2025 11:00:00 GMT</pubDate>
<description>Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa’s growing preclinical immunology portfolio Monte Rosa to receive an upfront payment of $120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory, and sales milestones, as well as tiered royalties on global net sales Extended cash runway enables Monte Rosa to accelerate preclinical and clinic</description>
</item>
<item>
<title>Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-second-110000220</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-second-110000220</guid>
<pubDate>Thu, 07 Aug 2025 11:00:00 GMT</pubDate>
<description>Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 2026 VAV1-directed MGD MRT-6160 advancing toward anticipated initiation of multiple Phase 2 studies in immune-mediated diseases Phase 1/2 study of GSPT1-directed MGD MRT-2359 advancing in heavily pretreated, castration-resistant prostate cancer patients; addition</description>
</item>
<item>
<title>Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-first-110000784</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-first-110000784</guid>
<pubDate>Mon, 21 Jul 2025 11:00:00 GMT</pubDate>
<description>MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial results anticipated in H1 2026 Additional Phase 1 cohort designed to evaluate potential early proof of concept in subjects with increased cardiovascular disease (CVD) risk and elevated CRP BOSTON, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, In</description>
</item>
<item>
<title>Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-announces-publication-science-181500542</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-announces-publication-science-181500542</guid>
<pubDate>Thu, 03 Jul 2025 18:15:00 GMT</pubDate>
<description>Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking new opportunities to address previously undruggable therapeutic targets Science, 3 July 2025 Molecular Glue Computational mining expands the target space for induced-proximity drugs BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, toda</description>
</item>
<item>
<title>Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-fda-110000210</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-announces-fda-110000210</guid>
<pubDate>Tue, 10 Jun 2025 11:00:00 GMT</pubDate>
<description>MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa’s clinical I&I portfolio Potency, selectivity, and long-lasting pharmacodynamics of MRT-8102 observed in preclinical studies create potential for clinical differentiation from competitive approaches for inflammatory diseases MRT-8102 Phase 1 clinical results, including data on safety, pharmacokinetics, NEK7 protein</description>
</item>
<item>
<title>Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-participate-jefferies-110000511</link>
<guid isPermaLink="true">https://6ix.com/company/monte-rosa-therapeutics-inc/news/monte-rosa-therapeutics-participate-jefferies-110000511</guid>
<pubDate>Wed, 28 May 2025 11:00:00 GMT</pubDate>
<description>BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 12:50 p.m. EDT. A webcast of the fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s websit</description>
</item>
</channel>
</rss>